For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Agios Pharmaceuticals, Inc.

USPTO Granted Patents = 96

CIPO Patents = 8

EPO Patents = 39

Trademarks = 27

Forward Citations = 592

Loading Chart...

Loading Chart...

79 inventors (with patents filed for the assignee):

Jeffrey O Saunders (31 out of 68 patents)

Francesco Gerald Salituro (30 out of 177 patents)

Jeremy Mark Travins (29 out of 52 patents)

4. Janeta Popovici-Muller (27 out of 45 patents)

5. Shunqi Yan (19 out of 27 patents)

6. Zhenwei Cai (16 out of 20 patents)

7. Giovanni Cianchetta (15 out of 21 patents)

8. Shin-San Michael Su (14 out of 15 patents)

9. Dawei Cui (13 out of 15 patents)

10. Rene Marc Lemieux (13 out of 21 patents)

11. Samuel V Agresta (11 out of 14 patents)

12. Ding Zhou (10 out of 22 patents)

13. Zhihua Sui (9 out of 108 patents)

14. Zenon D Konteatis (8 out of 14 patents)

15. Robert Zahler (7 out of 74 patents)

Core Competencies:

Therapeutic Compounds

Pyruvate Kinase Activators

Blood Disorders

Combination Therapy

Brain Tumors

Malignancies

Cellular Metabolic Processes

IDH-Mutant Inhibitors

Pharmaceutical Compositions

Phenylalanine Hydroxylase

Glutaminase Inhibitors

Therapeutically Active Compositions

96 patents: Sort by Forward Citations

1. 12428376 - Therapeutic compounds and compositions (2025-09-30),

2. 12377093 - Pyruvate kinase activators for use in therapy (2025-08-05),

3. 12133853 - Pyruvate kinase activators for use in treating blood disorders (2024-11-05),

4. 11957680 - Pyruvate kinase activators for use in treating blood disorders (2024-04-16),

5. 11919915 - Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations (2024-03-05),

6. 11878049 - Mitapivat therapy and modulators of cytochrome P450 (2024-01-23),

7. 11872225 - Pyruvate kinase modulators and use thereof (2024-01-16),

8. 11866411 - Therapeutic compounds and compositions (2024-01-09),

9. 11793806 - Pyruvate kinase activators for use in therapy (2023-10-24),

10. RE49582 - Therapeutic compounds and compositions (2023-07-17),

11. 11590132 - Pyruvate kinase activators for use in treating blood disorders (2023-02-28),

12. 11464775 - Pyruvate kinase modulators and use thereof (2022-10-11),

13. 11458127 - Methods of treating brain tumors using combination therapy (2022-10-04),

14. 11364240 - Pyruvate kinase activators for use in treating blood disorders (2022-06-21),

15. 11254652 - Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide (2022-02-22),

Agios Pharmaceuticals is a biopharmaceutical company dedicated to improving the lives of patients with genetically defined diseases. They focus on developing potentially transformative medicines that target key metabolic pathways to stop and potentially reverse the progression of these diseases. Agios combines scientific leadership, deep clinical development expertise, and a commitment to patient care to bring innovative therapies to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

96 Patents

#29 in Cambridge, MA

#213 in Massachusetts

#3,780 in US

#7,821 in the World

Cambridge, MA, United States of America

Agios Pharmaceuticals, Inc.

Forward Citations = 592

79 inventors:

Jeffrey O Saunders (31 out of 68 patents)

Francesco Gerald Salituro (30 out of 177 patents)

Jeremy Mark Travins (29 out of 52 patents)

4. Janeta Popovici-Muller (27 out of 45 patents)

5. Shunqi Yan (19 out of 27 patents)

Please report any incorrect information to support@idiyas.com

Loading…